Vaccines and Biotechnology city

VBC Launches Implementation Phase for Egypt’s First Locally Manufactured PCV13 Vaccine

Under the patronage and in the presence of H.E. Prof. Dr. Khaled Abdel Ghaffar, Minister of Health and Population, Vaccines and Biotechnology City (VBC) launched the implementation phase for localizing the first locally manufactured PCV13 vaccine in Egypt, signing the technology transfer agreement with Yuxi Walvax Biotechnology, its strategic technology partner with World Health Organization prequalified facilities.

Prof. Dr. Magdy El Sayed, CEO of VBC, opened the event by presenting the strategic vision for Egypt’s first locally made PCV13, along with the site’s readiness and bioprocessing capabilities, describing the milestone as a turning point for vaccine localization and national health security. The event brought together Dr. Hisham Stait, Chairman of the Egyptian Unified Procurement Authority (UPA); Dr. Tamer Elhoseiny, Vice Chairman of the Egyptian Drug Authority (EDA); Dr. Dong Shaozhong, Vice Chairman of Walvax Group and Chairman of Yuxi Walvax; Mr. Kamal Ebeed of the African Pooled Procurement Mechanism (APPM), Africa CDC; Mr. Yang Huazhi (Aaron), Director of the Global Sales Department at Walvax Group; Prof. Xuan-Yi Wang of Fudan University; and Prof. Dr. Mohamed Ghandour, Consultant in Pediatrics and Neonatology. The agreement was signed in the presence of H.E. the Minister, followed by a tour of VBC’s manufacturing facilities.

This partnership advances Egypt Vision 2030 and the African Union’s Agenda 2063, supporting vaccine self-sufficiency and strengthening supply security at the national and African levels.

Leave A Comment

WordPress Lightbox